دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention
Ralf E.HarskampMD, PhDaAlexander C.FanaroffMD, MHSbRenato D.LopesMD, PhDcDaniel M.WojdylaMScShaun G.GoodmanMD, MScdeLaine E.ThomasPhDcRonaldAronsonMDfStephanWindeckerMDgRoxanaMehranMDhChristopher B.GrangerMDcJohn H.AlexanderMD, MHSc
doi : 10.1016/j.jacc.2021.11.035
Volume 79, Issue 5, 8 February 2022, Pages 417-427
The use of apixaban instead of vitamin K antagonists (VKA) as well as dropping aspirin results in less bleeding and comparable ischemic events in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention treated with a P2Y12 inhibitor.
Patients With Atrial Fibrillation and PCI or ACS: Does Predicted Risk Matter?∗
PascalVranckxMD, PhDabDominick J.AngiolilloMD, PhDcMarcoValgimigliMD, PhDd
doi : 10.1016/j.jacc.2021.11.034
Volume 79, Issue 5, 8 February 2022, Pages 428-431
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin
MuthiahVaduganathanMD, MPHaNaveedSattarMD, PhDbJialinXuPhDcJavedButlerMD, MPH, MBAdKenneth W.MahaffeyMDeBruceNealMB, ChB, PhDfghWayneShawDSLiNormanRosenthalMDiMichaelPfeiferMDjMichael K.HansenPhDcJames L.JanuzziJr.MDk
doi : 10.1016/j.jacc.2021.11.027
Volume 79, Issue 5, 8 February 2022, Pages 432-444
Circulating biomarkers reflecting different mechanistic pathways may identify at-risk individuals with diabetes who may benefit from sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Eligibility and Response to Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Therapy: How Useful Are Cardiac Biomarkers?∗
Justin B.Echouffo-TcheuguiMD, PhDabElizabethSelvinPhD, MPHbc
doi : 10.1016/j.jacc.2021.11.028
Volume 79, Issue 5, 8 February 2022, Pages 445-447
Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair
Michael I.BrenerMDaPhilippLurzMD, PhDbJörgHausleiterMDcJosepRodés-CabauMDdNeilFamMDeSusheel K.KodaliMDaKarl-PhilippRommelMDbGuillemMuntané-CarolMDdMaraGavazzoniMDfTamim M.NazifMDaAlbertoPozzoliMDgHannesAlessandriniMDhAzeemLatibMDiLuigiBiascoMDjDanielBraunMDcEricBrochetMDkPaoloDentiMDlEdithLubosMDm…Rebecca T.HahnMDa
doi : 10.1016/j.jacc.2021.11.031
Volume 79, Issue 5, 8 February 2022, Pages 448-461
The right ventricular (RV)–pulmonary arterial (PA) coupling ratio relates the efficiency with which RV stroke work is transferred into the PA. Lower ratios indicate an inadequate RV contractile response to increased afterload.
Right Ventricle-Pulmonary Artery Coupling in Percutaneous Tricuspid Valve Repair: Is Simple Sufficient?∗
Lawrence G.RudskiMDJonathanAfilaloMD
doi : 10.1016/j.jacc.2021.11.030
Volume 79, Issue 5, 8 February 2022, Pages 462-464
Risk Stratification for Congenital Heart Surgery for ICD-10 Administrative Data (RACHS-2)
PhilipAllenMD, MSaFarhanZafarMDbJunhuiMiMSaSarahCrookPhDcJoyceWooMD, MSdNatalieJayaramMD, MSBeRooseveltBryantIIIMDfTaraKaramlouMD, MScgJamesTweddellMDbKacieDraganMPHhStephenCookMDiEdward L.HannanPhDjJane W.NewburgerMD, MPHkEmile A.BachaMDlRobertVincentMDmKhanhNguyenMDnKathleenWalsh-SpoonhowerMDoRalphMoscaMDp…Brett R.AndersonMD, MBA, MSc
doi : 10.1016/j.jacc.2021.11.036
Volume 79, Issue 5, 8 February 2022, Pages 465-478
As the cardiac community strives to improve outcomes, accurate methods of risk stratification are imperative. Since adoption of International Classification of Disease-10th Revision (ICD-10) in 2015, there is no published method for congenital heart surgery risk stratification for administrative data.
Cracking the Administrative Database Code to Risk Stratify Congenital Heart Disease Surgery∗
Keila N.LopezMD, MPHShaine A.MorrisMD, MPH
doi : 10.1016/j.jacc.2021.11.032
Volume 79, Issue 5, 8 February 2022, Pages 479-481
Interventions for Frailty Among Older Adults With Cardiovascular Disease: JACCÂ State-of-the-Art Review
NailaIjazMDaBrianButaMHSbQian-LiXuePhDcDenise T.MohessMDadArchanaBushanMDadHenryTranMDaWayneBatchelorMD, MHSaChristopher R.deFilippiMDaJeremy D.WalstonMDbcKarenBandeen-RochePhDbDaniel E.FormanMDeJon R.ResarMDfChristopher M.O’ConnorMDaGaryGerstenblithMDbfAbdulla A.DamlujiMD, PhDabf
doi : 10.1016/j.jacc.2021.11.029
Volume 79, Issue 5, 8 February 2022, Pages 482-503
With the aging of the world’s population, a large proportion of patients seen in cardiovascular practice are older adults, but many patients also exhibit signs of physical frailty. Cardiovascular disease and frailty are interdependent and have the same physiological underpinning that predisposes to the progression of both disease processes. Frailty can be defined as a phenomenon of increased vulnerability to stressors due to decreased physiological reserves in older patients and thus leads to poor clinical outcomes after cardiovascular insults. There are various pathophysiologic mechanisms for the development of frailty: cognitive decline, physical inactivity, poor nutrition, and lack of social supports; these risk factors provide opportunity for various types of interventions that aim to prevent, improve, or reverse the development of frailty syndrome in the context of cardiovascular disease. There is no compelling study demonstrating a successful intervention to improve a global measure of frailty. Emerging data from patients admitted with heart failure indicate that interventions associated with positive outcomes on frailty and physical function are multidimensional and include tailored cardiac rehabilitation. Contemporary cardiovascular practice should actively identify patients with physical frailty who could benefit from frailty interventions and aim to deliver these therapies in a patient-centered model to optimize quality of life, particularly after cardiovascular interventions.
Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week
MonaFiuzatPharmDaCarine E.HamoMD, MHSbJavedButlerMD, MPH, MBAcWilliam T.AbrahamMDdErsilia M.DeFilippisMDeGregg C.FonarowMDfJoannLindenfeldMDgRobert J.MentzMDaMitchell A.PsotkaMD, PhDhScott D.SolomonMDiJohn R.TeerlinkMDjMuthiahVaduganathanMD, MPHiOrlyVardenyPharmDkJohn J.V.McMurrayMDlChristopher M.O’ConnorMDah
doi : 10.1016/j.jacc.2021.11.033
Volume 79, Issue 5, 8 February 2022, Pages 504-510
With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of background drug therapy is necessary in clinical trials in patients with HF. The current paper summarizes the discussion and provides potential conceptual approaches, with a focus on therapies indicated for HF with reduced ejection fraction.
Long-Term Effects of Community-Based Lifestyle Interventions in Coronary Patients: RESPONSE-2 3-Year Follow-Up
ArnoTijssenMScHarald T.JørstadMD, PhDMadelonMinnebooMD, PhDGerbenter RietMD, PhDRobertLindeboomPhDWilma J.M.Scholte op ReimerPhDRon J.G.PetersMD, PhDMarjoleinSnatersePhD
doi : 10.1016/j.jacc.2021.11.038
Volume 79, Issue 5, 8 February 2022, Pages 511-512
Genetic Variants and Outcomes in Nonischemic Dilated Cardiomyopathy: The Role of miRNAs
SalvatorePatanèMD
doi : 10.1016/j.jacc.2021.10.048
Volume 79, Issue 5, 8 February 2022, Page e161
